Screening Bactericidal Action of Cytoplasm Extract from Kumazasa Bamboo (Sasa veitchii) Leaf against Antibiotics-Resistant Pathogens such as MRSA and VRE Strains

Shoichi Shirotake*†, Jutaro Nakamura†, Akiko Kaneko, Eri Anabuki, and Naoto Shimizu

Department of Pharmaco-Therapeutics, Graduate School of Medicine, Yokohama City University, Fuku’ura3-9, Knazawa-ku, Yokohama, 236-004, Japan

* These authors contributed equally to this manuscript

Abstract

We aimed to develop a new treatment against antibiotic-resistant bacteria by focusing on cytoplasm of Kumazasa bamboo leaf. The cytoplasmic extract displays potent bactericidal action against Gram-positive bacteria such as Staphylococcus aureus, Enterococci and Streptococcus pneumoniae and also multi-antibiotic resistant MRSA (methicillin-resistant Staphylococcus aureus) and VRE (vancomycin-resistant Enterococci) strains. It induced bacteriolysis by firmly aggregating MSSA (methicillin-susceptible Staphylococcus aureus) and MRSA, and by lysis of VSE (vancomycin-susceptible Enterococci) and VRE. Clinical isolates of MRSA (30 strains in total) were susceptible to this extract, which gave MICs of Kumazasa-cytoplasmic extract ranging from 1.6 to 6.3%. The antibacterial action was bactericidal on scanning electron microscopy (SEM) analysis. A synergistic effect of this extract with ampicillin (ABPC) was obviously observed in all MRSA strains. The synergistic effect with vancomycin (VCM) was observed against VRE. The combination with clarithromycin (CAM) or tetracycline (TC) additively enhanced the antibacterial activity of CAM against CAM-susceptible Enterococci strains, and also that of TC against TC-resistant VRE strains.

The present results should encourage research on antibacterial–hydrophilic ingredients derived from Kumazasa for use against antibiotic-resistant bacteria. The combination of Kumazasa-cytoplasmic extract with a cell wall synthesis inhibitor (ABPC or VCM) will be a highly efficient treatment for infections caused by multidrug-resistant MRSA and VRE strains.

Keywords: Kumazasa bamboo; Cytoplasm; Bactericidal action; Synergistic effect; Antibiotic; Multi-antibiotic resistance; MRSA; VRE

Introduction

More than 50 years of widespread use of antibiotics has resulted in the gradual appearance of antibiotic-resistant bacteria (Noble et al., 1992; Bozdogan et al., 2003). Methicillin-resistant Staphylococcus aureus (MRSA, detection rate: ca 80%) (Uehara et al., 2000) have acquired resistance due to the meca gene, which encodes an altered penicillin-binding protein with reduced affinity for methicillin. In recent years, vancomycin-resistant Enterococci (VRE) and vancomycin–resistant Staphylococcus aureus (VRSA) have appeared (detection rate for VRE; 20% or more of Enterococci in intensive care units in Europe and the U.S.A) (Frieden et al., 1993). One of the biggest therapeutic issues at the moment is the emergence of multiple antibiotic-resistant pathogenic bacteria which is very dangerous.

For thousands of years, plants have proved to be a rich source of biologically active compounds. Indeed throughout human history, plant extracts have been used to cure various chronic diseases. In recent years, numerous therapeutically useful drugs have been extracted from plants, (Kumarasamy et al., 2002; Coutinho et al., 2009) such as Aspirin, Kinin, Artemisinin, Taxol and Camptothecin. Plants have developed some unique antibacterial mechanisms against infection. Traditional medicines, such as mixtures of oriental herbs (Coutinho et al., 2009) and tea applications.

In Japan, Kumazasa bamboo (Sasa veitchii) leaf have been used as SUSHI sheets or to package rice balls (known as CHIMAKI) to protect food from rotting due to the growth of bacteria. The traditional medicine from Kumazasa has a wide range of applications such as treatment of halitosis and body odor, stomatitis, gingivitis, bedsores, burns, hemorrhoids, cuts and purulent wounds. Organic solvent extracts (e.g., using diethyl ether) from leaves of Kumazasa (Sasa albo-marginata) were reported to possess antimicrobial activity against bacteria, fungi, etc.
and yeast (Chuyen et al., 1982). To date, no studies have been conducted to investigate the antibacterial activity in the organic extracts against antibiotic-resistant bacterial strains. Herein, we examine the cytoplasmic extract from Kumazasa leaf in terms of its antibacterial activity against multidrug-resistant pathogens.

Materials and Methods

Cytoplasmic Extraction from Kumazasa Bamboo Leaf

The cytoplasm hydrophilic extraction was obtained by removing resin and lignin from green leaves of striped Kumazasa (Sasa veitchii), as following. Fresh Kumazasa leaves were crushed and homogenized by a mixer, then steeped in a 3%NaOH solution at room temperature overnight (the cell membrane was destroyed by alkaline hydrolysis). The pH value of the solution was adjusted to 4, by dropping H₂SO₄ solution, and the residue was collected by centrifugation (×15000rpm), then the residue was dissolved at concentration of 40mg/ml in warm distilled-water as a green-colloidal solution, then the pH value was adjusted to 7.4, by dropping NaOH solution (cytoplasmic crude extraction).

Bacterial Strains

Methicillin-susceptible Staphylococcus aureus (MSSA); ATCC6538 and JCM2874, Methicillin-resistant Staphylococcus aureus (MRSA); JCM8703 and N315. Vancomycin-sensitive Enterococcus faecium (VSE); JCM5804, Vancomycin-resistant Enterococcus faecalis (VRE); GTC02000 and NCTC12201. Clinical isolates of MRSA (30 isolates) were provided by Yokohama-City University Hospital (Yokohama, Japan).

Determination of Antibacterial Activity and Combination Effect with Antibiotic

The minimum inhibitory concentrations (MICs) of Kumazasa medicine were determined by the microbroth dilution methods (National Committee for Clinical Laboratory Standards Institute, 1997). A dilute suspension of bacteria was inoculated into each well of a 96-well microplate, and the range of Kumazasa-cytoplasmic extract was 1.25% to 0.2% in the MH broth (Difco.). The final inoculum of bacteria was approximately 7.5X10⁴ cells/well by MacFarland. MBCs (Peterson and Shanholzer, 1997) were defined as the lowest concentration of antimicrobial agent where was no bacterial growth on LB agar plates (Difco.).

The antibacterial effects of a combination of antibiotics and Kumazasa was assessed by the checkerboard method (White et al., 1996).

Morphological Analysis of MRSA and VRE

MRSA and VRE were incubated in MH broth with or without Kumazasa medicine and/or antibiotics for 24hr. After incubation, culture suspension was filtered using Nuclepore Track-Etch membrane of pore size 0.1 um (Whatman Inc, Clifton, NJ USA). Morphological changes of MRSA and VRE were assessed by scanning electron microscopy (type:S-800, Hitachi Corp., Tokyo, Japan).

Results and Discussion

Plants have developed unique antibacterial mechanisms for protection against infection. In this study, we focused on anti-
A combination of Kumazasa-CE. Such synergistic effect was not observed on vancomycin-susceptible Enterococci (VSE:JCM5804). Each tested by triplicate.

**Figure 2C:** Synergistic effect of Kumazasa-CE with ABPC against clinically isolated methicillin-resistant Staphylococcus aureus strains (MRSA). Synergistic effect was observed against all MRSA strains (clinical isolated 30 strains). Each tested by triplicate.

bacterial action in cytoplasm of Kumazasa leaf. The antimicrobial activity (as MIC) of cytoplasmic extract from Kumazasa or each antibiotic (ampicillin: ABPC, vancomycin: VCM, clarithromycin: CAM, or tetracycline: TC) was measured against both Gram-positive and Gram-negative microbes (in Table 1). The Kumazasa-cytoplasmic extract (Kumazasa-CE) displayed a markedly potent antibacterial activity against Gram-positive bacteria such as *Staphylococcus aureus*, *Enterococci* and *Streptococcus pneumoniae* (MICs; 0.8-6.3 (v/v) %, 1% Kumazasa-CE contained 0.4mg of the dry extract). The antibacterial activity against Gram-positive bacteria is much stronger than that against Gram-negative bacteria such as *E.coli* or *P.aeruginosa* (MICs of Kumazasa medicine >25% in both cases) (in Table 1), because of the hydrophilic property of this extract. The Kumazasa-CE displayed strong antimicrobial activity (MICs; 0.8-6.3 (v/v) %) against both antibiotic-susceptible and -resistant *Staphylococcus aureus* and *Enterococci* strains, such as MSSA and MRSA, or VSE and VRE, respectively. Furthermore, this extract is also effective against multi-antibiotic resistant MRSA and VRE, although MRSA and VRE were simultaneously resistant to many antibiotics (in Table 1). Clinical isolates of MRSA (30 strains in total) were also tested, which gave MICs of Kumazasa-CE ranging from 1.6 to 6.3%. The MICs were compared with 16 to 128 times dilution of Kumazasa-CE, and the MIC value was corresponded to the Minimum bactericidal concentration value (MBC (Peterson and Shanholzer, 1997)). Scanning electron microscopy (SEM) images clearly showed that this extract induces firm aggregation of MRSA (in Fig.1A). This firm aggregation is a characteristic action to *Staphylococcus aureus*. Using VRE (NCTC12201), bacteriolysis was clearly observed after addition of this extract alone, but the firm aggregation was not evident from the SEM images (in Fig.1B). SEM analysis unmistakably showed the bacteriolytic action of this extract against VRE (in Fig.1B). Such antibacterial action was clear against also each antibiotic-susceptible strain on SEM image (data not shown). The cytoplasmic extract from Kumazasa displays surely bactericidal action against Gram-positive strains and also the multiple antibiotic-resistant bacteria as MRSA and VRE strains.

The synergistic effect was examined by checkerboard methods (White et al., 1996) in combination between this cytoplasmic extract and antibiotics (ABPC, VCM, CAM, and TC). ABPC and VCM inhibit a synthesis of bacterial cell-wall on binding to the target site on the cell-wall, while CAM and TC inhibit a protein synthesis on binding target enzyme inside of cell. The combination effect with antibiotic was evaluated by fractional inhibitory concentration (FIC) index in the method. FIC index ≤ 0.5 were judged to be a synergistic effect; 0.5<FIC index ≤ 1.0 for an additive effect; 1.0<FIC index ≤ 2.0 no effect, as shown in Table 2.
Table 1: The antibacterial activity of cytoplasmic extract from Kumazasa and antibiotics against antibiotic-susceptible and –resistant bacteria.

<table>
<thead>
<tr>
<th>Antibiotic</th>
<th>MSSA ATCC6538</th>
<th>MRSA N315</th>
<th>MRSA JCM8703</th>
<th>MSSA ATCC6538</th>
<th>MRSA JCM8703</th>
<th>MRSA JCM8703 (clinical isolate)</th>
<th>VSE JCM5804</th>
<th>VRE GTC02000</th>
<th>VRE NCTC12201</th>
<th>S. pneumoniae ATCC262</th>
<th>E. coli ATCC12923</th>
<th>P. aeruginosa ATCC12924</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABPC</td>
<td>640</td>
<td>320</td>
<td>1240</td>
<td>640</td>
<td>1240</td>
<td>2005</td>
<td>2520</td>
<td>1240</td>
<td>640</td>
<td>10000</td>
<td>10000</td>
<td></td>
</tr>
<tr>
<td>VCM</td>
<td>0.063</td>
<td>1</td>
<td>0.5</td>
<td>&gt;128</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>1</td>
<td>8</td>
<td>&gt;128</td>
</tr>
<tr>
<td>CAM</td>
<td>1.063</td>
<td>1</td>
<td>0.25</td>
<td>&gt;128</td>
<td>2</td>
<td>&gt;128</td>
<td>1.063</td>
<td>1</td>
<td>2</td>
<td>&gt;128</td>
<td>&gt;128</td>
<td>&gt;128</td>
</tr>
<tr>
<td>TC</td>
<td>0.125</td>
<td>0.125</td>
<td>0.5</td>
<td>0.125</td>
<td>0.125</td>
<td>0.125</td>
<td>0.125</td>
<td>0.125</td>
<td>0.125</td>
<td>0.125</td>
<td>0.125</td>
<td>0.125</td>
</tr>
</tbody>
</table>

MIC of Kumazasa-cytoplasmic extraction was calculated as the concentration of the dry crude-extract.

MIC…susceptible, MIC…intermediate resistant, MIC…resistant (by CLSI; MIC Interpretive Standards), Each tested by triplicate.

MSSA:methicillin-susceptible Staphylococcus aureus.
MRAS:methicillin-resistant Staphylococcus aureus.
VSE:vancomycin-susceptible Enterococci.
VRE:vancomycin-resistant Enterococci.


Table 2: Fractional inhibitory concentration index and Synergistic evaluation on a combination of cytoplasmic extract from Kumazasa with antibiotics against MSSA, MRSA, VSE, and VRE.

<table>
<thead>
<tr>
<th>Antibiotic</th>
<th>MSSA</th>
<th>MRSA</th>
<th>VSE</th>
<th>VRE</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABPC</td>
<td>FIC</td>
<td>FIC</td>
<td>FIC</td>
<td>FIC</td>
</tr>
<tr>
<td>VCM</td>
<td>FIC</td>
<td>FIC</td>
<td>FIC</td>
<td>FIC</td>
</tr>
<tr>
<td>CAM</td>
<td>FIC</td>
<td>FIC</td>
<td>FIC</td>
<td>FIC</td>
</tr>
<tr>
<td>TC</td>
<td>FIC</td>
<td>FIC</td>
<td>FIC</td>
<td>FIC</td>
</tr>
</tbody>
</table>

Fractional inhibitory concentration index value (FIC) was calculated by the checkerboard method.20

Synergy defined as an FIC of <0.5, Additive as 0.5 <FIC <1; Each tested by triplicate.

*Not calculated because of a high resistance (MIC >128µg/ml).

MSSA:methicillin-susceptible Staphylococcus aureus.
MRAS:methicillin-resistant Staphylococcus aureus.
VSE:vancomycin-susceptible Enterococci.
VRE:vancomycin-resistant Enterococci.


Table 2: Fractional inhibitory concentration index and Synergistic evaluation on a combination of cytoplasmic extract from Kumazasa with antibiotics against MSSA, MRSA, VSE, and VRE.
The combination with ABPC strengthened the antibacterial activity of ABPC against MRSA, since MICs of ABPC diminished in a dose-dependent manner (Fig. 2). The FIC index values were under 0.5 indicating the synergistic effect on antibacterial activity of ABPC. Although the synergistic effect of the components in tea, such as catechins, flavonoids and polyphenols, with β-lactam antibiotic against MRSA strains has been reported, (Cho et al., 2008; Xu and Lee, 2001; Falcão-Silva et al., 2009) the precise-synergistic mechanism remained unclear. As observed from the present SEM images (in Fig.1A), the combination with ABPC resulted in firm aggregation of MRSA, which then triggered bacteriolysis from mycelia caking change. Our SEM analysis indicated that the synergistic effect is derived from a combination of both bacterial aggregation, mediated by this extract, and morphological transformation, mediated by ABPC. A combination of this extract with VCM synergistically enhanced the antimicrobial activity of VCM against VRE, but did not affect against susceptible Enterococci (Fig.2 and Table2). Moreover, the observed bacteriolytic activity against VRE (NCTC122201) by co-administration of VCM and this extract was greater than anticipated from the sum of the antibacterial activities of VCM or the Kumazasa-CE alone (i.e., a non additive effect). This synergistic effect with VCM is a novel finding. The combination effect was not observed against the strains susceptible to ABPC or VCM (in Table 2). Interestingly, the efficacy of this extract is closely related to an inhibitor of bacterial cell-wall synthesis on multi-antibiotic resistant MRSA and VRE strains.

The synergistic effect on CAM could not be measured because of the strong resistance of MRSA to CAM (MIC >128 μg/ml). The antibacterial activity of CAM was increased by half upon using 0.8% of the Kumazasa-CE against MSSA susceptible to CAM, showing an additive effect. However, the extracts at concentrations 0-0.4% did affect the MIC values of CAM. Similarly, the antimicrobial activity of CAM was enhanced by a combination of this extract against VSE and VRE(GTC0200), which are susceptible to CAM. However, such combination effect could not be detected against VRE(12201), which is strongly resistant to CAM. This extract additionally enhanced the antibacterial activity of TC against MRSA (JCMB8703, and clinical isolate 2005) and VRE (GTC02000 and NCTC12201) in checkerboard method, however it was not obtained against TC-highly resistant and susceptible Staphylococcus aureus strains (in Tables 1 and 2). The target sites for both CAM and TC are intracellular, and the resistant mechanism consists of a modulation on target sites and an acceleration of efflux pump. Herbal extracts were reported to reinforce synergistically the antibacterial activity by inhibition of the efflux pump for antibiotics (Rosato et al., 2007; Lee et al., 2008; Coutinho et al., 2009). No such synergistic effect between this extract and CAM and/or TC was observed from the SEM images or from the fractional inhibitory concentrations determined using the checkerboard method. The absence of synergistic action in this extract is presumably because the target sites for both CAM and TC are intracellular.

Although there is no question concerning the observed synergistic effect between the Kumazasa-cytoplasmic extract and ABPC or VCM against antibiotic-resistant bacteria (e.g., MRSA or VRE), the precise mechanism of action needs further study. Furthermore, heat treatment of this Kumazasa extract using an autoclave had no effect on the observed antibacterial activity and the synergistic effect (data not shown). Therefore, the active components are heat stable. Kumazasa leaf contains many ingredients, as minerals, vitamins, polysaccharides, flavonoids, and other macromolecules (Chuyen et al., 1982). The present results should encourage research on antibacterial–hydrophilic ingredients derived from Kumazasa for use against antibiotic-resistant pathogen.

We conclude that the cytoplasmic extract from Kumazasa leaf displayed the unique bactericidal action against multi-antibiotic resistant MRSA and VRE strains, and that the combination with a cell wall synthesis inhibitor (ABPC or VCM) will be a highly efficient treatment for infections caused by multdrug-resistant MRSA and VRE strains.

Acknowledgements

The clinical isolated MRSA strains were kindly provided by T.Mituda, Yokohama City Univ. Hospital. The authors thank N.Sasatu, Tokyo Pharmacy Univ.,and T.Toyo'oka, Sizuoka Univ. for valuable comments, and N.Hotoki for technical assistance. This work was supported by Grants-Aid for Scientific Research (No. 20659069 to S.S.) from the Ministry of Education, Culture, Sports, Science and Technology of Japan, and partly by the Grant for 2008 Strategic Research Project (No. K20028) of Yokohama City Univ., Japan.

Author Contributions

S.S. led the discovery, designed and extraction from Kumazasa-CE, J.N. and A.K. measured antibacterial activity. E.A and N.S. coordinated synergistic effect and SEM analyses.

References


